← Oncology Approval Tracker

FDA DECISION ·

Jemperli

dostarlimab-gxly · GSK

FDA approvalNew or expanded indicationEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with primary advanced or recurrent endometrial cancer; use with carboplatin and paclitaxel followed by single-agent dostarlimab.

LAMPGEN ANALYSIS

Why it matters

The label expanded from dMMR or MSI-high disease to a broader endometrial cancer population.

What research teams should watch

Continue recording MMR status for subgroup interpretation and verify the switch from combination to maintenance dosing.

PRIMARY RECORDS

Sources